Citations

Showing 10 of 108162 citations.

Benefits of biologic therapy administered for asthma on co‐existent chronic rhinosinusitis: A real‐world study
Bajpai, Shilpika , Marino, Michael J. , Rank, Matthew A. , Donaldson, Angela M. , O’Brien, Erin K. , Lal, Devyani , Lal, Devyani , O'Brien, Erin K

Mayo Clinic

International Forum of Allergy & Rhinology | February 3, 2021 | Volume: 11 | Issue: 8 | Pages: 1152-1161

10.1002/alr.22774 | PMID 33527730 Get It

BackgroundAsthma and some chronic rhinosinusitis (CRS) subtypes are mediated by similar pathophysiologic mechanisms. The purpose of this study was to evaluate the effects of biologic therapy for asthma on co‐existent CRS in the “real‐world” setting.MethodsA review of electronic health records (2016‐2019) at Mayo Clinic was conducted to identify asthma patients treated with biologics who had co‐existent CRS. Matched‐pair analyses compared pretherapy and posttherapy Lund‐Mackay computed tomography (CT) scores and 22‐item Sino‐Nasal Outcome Test (SNOT‐22) scores. Performance of endoscopic sinus surgery (ESS) after initiating biologics was studied.ResultsWe identified 247 patients who received anti‐asthma biologic therapy and had co‐existent CRS. Of these, 181 patients (73.3%) had CRS with nasal polyposis (CRSwNP) and 66 (26.7%) had CRS without nasal polyposis (CRSsNP). The biologics utilized were omalizumab (51.0%), mepolizumab (46.6%), benralizumab (10.5%), reslizumab (1.6%), and dupilumab (2.4%). Anti‐interleukin‐5 (anti‐IL‐5) intervention was associated with significant improvement in CT scores (CRS overall, CRSwNP subgroup, CRSsNP subgroup) and SNOT‐22 scores (CRS overall, CRSwNP subgroup). Patients on omalizumab had a decrease in CT scores, but not SNOT‐22 scores. ESS was performed in 206 patients (84.1%); 55 (22.3%) underwent surgery post–biologic intervention (anti‐IL‐5: 16.5%; omalizumab 27.8% of patients).ConclusionAnti‐IL‐5 agents were associated with improved CT and SNOT‐22 scores in the overall CRS group and in CRSwNP subgroup; CRSsNP patients showed improved CT scores only. Omalizumab improved CT but not SNOT‐22 scores. ESS was performed in 22% of patients after initiating biologics. These real‐world results may influence future trial designs and clinical applications of biologics for CRS. ©2021 ARSAAOA, LLC.
Declining Medicare Reimbursement for Urologists: An Opportunity for Informed Advocacy
Edmonds, Victoria S. , Haglin, Jack M. , Tyson, Mark D.

Mayo Clinic

Journal of Urology | February 3, 2021 | Volume: 206 | Issue: 1 | Pages: 10-12

10.1097/ju.0000000000001655 | PMID 33533637 Get It

Recognizing the Importance of Chest Surgery for Transmasculine Youth
Kuper, Laura E. , Rider, G. Nic , Amand, Colt M. St., St Amand, Colt M, Rider, G. Nic

Mayo Clinic

Pediatrics | February 3, 2021 | Volume: 147 | Issue: 3 | Pages: No page available

10.1542/peds.2020-029710 | PMID 33536331 Get It

The Value of Patient Perspectives in an Ethical Analysis of Recruitment and Consent for Intracranial Electrophysiology Research
Richardson, Jordan , Balzekas, Irena , Richardson, Jordan P , Lundstrom, Brian Nils, Sharp, Richard R , Lundstrom, Brian N. , Worrell, Gregory A. , Sharp, Richard R.

Mayo Clinic

AJOB Neuroscience | February 3, 2021 | Volume: 12 | Issue: 1 | Pages: 75-77

10.1080/21507740.2020.1866114 | PMID 33528326 Get It

Rurality, Death, and Healthcare Utilization in Heart Failure in the Community
Manemann, Sheila M., Henning‐Smith, Carrie , Rutten, Lila J. Finney , Chamberlain, Alanna M. , Fabbri, Matteo, Weston, Susan A., Jiang, Ruoxiang , Roger, Véronique L. , St Sauver, Jennifer, Finney Rutten, Lila J , Chamberlain, Alanna M , Sauver, Jennifer L. St.

Mayo Clinic

Journal of the American Heart Association | February 3, 2021 | Volume: 10 | Issue: 4 | Pages: No page available

10.1161/jaha.120.018026 | PMID 33533260 Get It

Background Prior reports indicate that living in a rural area may be associated with worse health outcomes. However, data on rurality and heart failure (HF) outcomes are scarce. Methods and Results Residents from 6 southeastern Minnesota counties with a first‐ever code for HF ( International Classification of Diseases, Ninth Revision [ ICD‐9 ], code 428, and International Classification of Diseases, Tenth Revision [ ICD‐10 ] code I50) between January 1, 2013 and December 31, 2016, were identified. Resident address was classified according to the rural‐urban commuting area codes. Rurality was defined as living in a nonmetropolitan area. Cox regression was used to analyze the association between living in a rural versus urban area and death; Andersen‐Gill models were used for hospitalization and emergency department visits. Among 6003 patients with HF (mean age 74 years, 48% women), 43% lived in a rural area. Rural patients were older and had a lower educational attainment and less comorbidity compared with patients living in urban areas ( P <0.001). After a mean (SD) follow‐up of 2.8 (1.7) years, 2440 deaths, 20 506 emergency department visits, and 11 311 hospitalizations occurred. After adjustment, rurality was independently associated with an increased risk of death (hazard ratio [HR], 1.18; 95% CI, 1.09–1.29) and a reduced risk of emergency department visits (HR, 0.89; 95% CI, 0.82–0.97) and hospitalizations (HR, 0.78; 95% CI, 0.73–0.84). Conclusions Among patients with HF, living in a rural area is associated with an increased risk of death and fewer emergency department visits and hospitalizations. Further study to identify and address the mechanisms through which rural residence influences mortality and healthcare utilization in HF is needed in order to reduce disparities in rural health.
Optimization of anti‐pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. Cephalosporins and penicillins latest update
Epps, Quovadis J., Epps, Kevin , Zobell, Jeffery T. , Epps, Kevin L

Mayo Clinic

Pediatric Pulmonology | February 3, 2021 | Volume: 56 | Issue: 6 | Pages: 1784-1788

10.1002/ppul.25282 | PMID 33524241 Get It

Clinical characterization of primary hyperoxaluria type 3 in comparison with types 1 and 2
Singh, Prince , Viehman, Jason K., Mehta, Ramila A. , Cogal, Andrea G. , Hasadsri, Linda , Oglesbee, Devin , Seide, Barbara M., Sas, David J. , Harris, Peter C. , Milliner, Dawn S. , Olson, Julie B, Harris, Peter C , Oglesbee, Devin , Olson, Julie B, Lieske, John C.

Mayo Clinic

Nephrology Dialysis Transplantation | February 3, 2021 | Volume: 37 | Issue: 5 | Pages: 869-875

10.1093/ndt/gfab027 | PMID 33543760 Get It

Abstract Background Primary hyperoxaluria (PH) type 3 (PH3) is caused by mutations in the hydroxy-oxo-glutarate aldolase 1 gene. PH3 patients often present with recurrent urinary stone disease in the first decade of life, but prior reports suggested PH3 may have a milder phenotype in adults. This study characterized clinical manifestations of PH3 across the decades of life in comparison with PH1 and PH2. Methods Clinical information was obtained from the Rare Kidney Stone Consortium PH Registry (PH1, n = 384; PH2, n = 51; PH3, n = 62). Results PH3 patients presented with symptoms at a median of 2.7 years old compared with PH1 (4.9 years) and PH2 (5.7 years) (P = 0.14). Nephrocalcinosis was present at diagnosis in 4 (7%) PH3 patients, while 55 (89%) had stones. Median urine oxalate excretion was lowest in PH3 patients compared with PH1 and PH2 (1.1 versus 1.6 and 1.5 mmol/day/1.73 m2, respectively, P &lt; 0.001) while urine calcium was highest in PH3 (112 versus 51 and 98 mg/day/1.73 m2 in PH1 and PH2, respectively, P &lt; 0.001). Stone events per decade of life were similar across the age span and the three PH types. At 40 years of age, 97% of PH3 patients had not progressed to end-stage kidney disease compared with 36% PH1 and 66% PH2 patients. Conclusions Patients with all forms of PH experience lifelong stone events, often beginning in childhood. Kidney failure is common in PH1 but rare in PH3. Longer-term follow-up of larger cohorts will be important for a more complete understanding of the PH3 phenotype.
Young platelet millionaires with essential thrombocythemia
Gangat, Naseema , Jawaid, Tabinda , Hanson, Curtis A. , Pardanani, Animesh , Tefferi, Ayalew , Pardanani, Animesh , Tefferi, Ayalew , Szuber, Natasha

Mayo Clinic

American Journal of Hematology | February 3, 2021 | Volume: 96 | Issue: 4 | Pages: No page available

10.1002/ajh.26114 | PMID 33524176 Get It

Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management
Pardanani, Animesh

Mayo Clinic

American Journal of Hematology | February 3, 2021 | Volume: 96 | Issue: 4 | Pages: 508-525

10.1002/ajh.26118 | PMID 33524167 Get It

AbstractOverviewSystemic mastocytosis (SM) results from a clonal proliferation of abnormal mast cells (MC) in extra‐cutaneous organs.DiagnosisThe major criterion is presence of multifocal clusters of spindled MC in the bone marrow. Minor diagnostic criteria include elevated serum tryptase level, abnormal MC CD25 expression, and presence of KITD816V mutation.Risk StratificationEstablishing SM subtype as per the World Health Organization classification system is an important first step. Broadly, patients either have indolent/smoldering SM (ISM/SSM) or advanced SM, the latter includes aggressive SM (ASM), SM with associated hematological neoplasm (SM‐AHN), and mast cell leukemia (MCL). Identification of poor‐risk mutations (ie, ASXL1, RUNX1, SRSF2, NRAS) further refines the risk stratification. Recently, clinical and hybrid clinical‐molecular risk models have been developed to more accurately assign prognosis in SM patients.ManagementTreatment goals for ISM patients are primarily directed towards anaphylaxis prevention/symptom control/osteoporosis treatment. Patients with advanced SM frequently need MC cytoreductive therapy to ameliorate disease‐related organ dysfunction. High response rates have been seen with small‐molecule inhibitors that target mutant‐KIT, including midostaurin (Food and Drug Administration approved) or avapritinib (investigational). Other options for MC cytoreduction include cladribine or interferon‐α, although head‐to‐head comparisons are lacking. Treatment of SM‐AHN primarily targets the AHN component, particularly if an aggressive disease such as acute myeloid leukemia is present. Allogeneic stem cell transplant can be considered in such patients, or in those with relapsed/refractory advanced SM. Imatinib has a limited therapeutic role in SM; effective cytoreduction is limited to those with imatinib‐sensitive KIT mutations.
Nonalcoholic Steatohepatitis, Sarcopenia, and Liver Transplantation
Bhanji, Rahima A. , Saiman, Yedidya , Watt, Kymberly D.

Mayo Clinic

Clinical Liver Disease | February 3, 2021 | Volume: 17 | Issue: 1 | Pages: 2-5

10.1002/cld.1000 | PMID 33552477 Get It